Semaglutide Oral vs NA-931
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Rybelsus
Oral semaglutide is the pill version of the same GLP-1 peptide found in Ozempic and Wegovy, sold for type 2 diabetes as Rybelsus. The trick that makes it work is an absorption enhancer called SNAC, which shields the peptide from stomach acid and helps it cross the gut lining. Lower doses are approved for diabetes, and higher 25 mg doses have now been approved as the first GLP-1 pill for weight loss.
Also: Bioglutide, cyclic glycine-proline
NA-931 (Bioglutide) is cyclic glycine-proline, a two-amino-acid ring that occurs naturally as a breakdown product of IGF-1. Its developer, Biomed Industries, describes it as an oral once-daily agonist at four receptors at once - IGF-1, GLP-1, GIP and glucagon - and has reported 13 to 15 percent weight loss in a 126-person Phase 2 trial. Those numbers have only ever appeared in conference abstracts, never in a peer-reviewed paper, and no trial results have been filed to ClinicalTrials.gov. The same molecule is already sold as a consumer brain-health supplement and as a Sigma-Aldrich catalogue chemical, which makes it unusually cheap to source and unusually hard to verify.
Key Comparison Insights
- Semaglutide Oral is FDA approved, while NA-931 remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Semaglutide Oral has stronger research evidence (FDA Approved) compared to NA-931 (Phase II Completed, Unpublished).
Detailed Comparison
| Attribute | Semaglutide Oral | NA-931 |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The active drug is identical semaglutide, a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and boosts glucose-dependent insulin release. The hard part is getting a delicate peptide through the stomach intact, because enzymes there normally destroy it. Each tablet co-formulates semaglutide with SNAC (sodium N-(8-[2-hydroxybenzoyl]amino) caprylate), which raises the local pH around the tablet, protects the peptide from breakdown, and helps it slip across the gastric lining into the blood. That is also why the pill must be taken on an empty stomach with a small sip of water and then nothing else for about 30 minutes, since food and extra fluid wreck absorption. | Cyclic glycine-proline is a diketopiperazine: glycine and proline joined into a small ring, 154 daltons, roughly a thirtieth the size of tirzepatide or retatrutide. The independent literature, mostly from Jian Guan's group in Auckland, describes a single mechanism: cGP competes with IGF-1 for binding to IGFBP-3, which frees up IGF-1 that was otherwise bound and inactive. That is a bioavailability effect, studied for stroke recovery, Parkinson's and blood pressure rather than for weight. Biomed's own patent filing (WO2025160184A1) goes much further, claiming the same molecule is a 'quadruple receptor agonist' at IGF-1, GLP-1, GIP and glucagon receptors. That claim is worth understanding properly, because it is the entire basis of the weight-loss story. GLP-1, GIP and glucagon receptors are class B GPCRs, the kind that normally need a thirty-plus residue peptide wrapping into the receptor's binding groove to switch on. A 154-dalton ring activating all three would be a genuinely significant pharmacological finding. No independent group has reported it. Searching PubMed for cyclic glycine-proline alongside GLP-1 returns nothing at all. |
| Common Dosing | Limited community data available See research protocols | 120 mg daily, oral Once daily |
| Administration | Oral tablet on empty stomach with <4oz water | Oral capsule or tablet, once daily |
| Typical Duration | Long-term / chronic use | 28 days in Phase 1, 13 weeks in Phase 2 |
| Best Time to Take | Before bed or morning (fasted) | Consistent daily timing |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is well-studied with large, published human trials, not preliminary work. The PIONEER program enrolled over 9,500 people with type 2 diabetes and showed oral semaglutide lowered A1C by roughly 0.6 to 1.4 percentage points and produced modest weight loss, generally matching or beating comparators like sitagliptin and empagliflozin. PIONEER PLUS, published in The Lancet, tested higher 25 mg and 50 mg doses and found greater A1C and weight reductions than the standard 14 mg. For obesity specifically, the OASIS trials moved to higher doses: OASIS 1 showed about 15.1% weight loss on 50 mg versus 2.4% on placebo, and OASIS 4 (NEJM, 2025) showed roughly 13.6% loss at 64 weeks on 25 mg, comparable to the injectable Wegovy dose. Side effects are the usual GLP-1 GI complaints. The honest tradeoff: it is real and effective, but absorption is finicky and the strict empty-stomach dosing rule matters more than people expect. | There are no peer-reviewed publications on NA-931. Not one. Everything in circulation is a conference abstract, and the abstracts carrying the efficacy numbers list Biomed's CEO as sole author with conflicts declared as 'None'. Two trials have completed, both run entirely in Australia: a 74-person Phase 1 (NCT06615700, completed September 2024) and a 126-person Phase 2 (NCT06564753, completed April 2025). Neither has results posted. A third trial (NCT06732245) would run in the US, Australia and New Zealand, but has not started recruiting. The reported weight loss is where this gets difficult. The same 126-person Phase 2 has been presented three times with three different numbers: 14.8 percent at ADA in June 2025, 13.8 percent at ENDO in July, and 13.8 percent with a different placebo-adjusted figure in a September press release. Enrolment is given as 125 in the abstracts against 126 on the registry. A result that moves between presentations is not yet a result. The company's website states NA-931 is in Phase 3. No Phase 3 trial for NA-931 is registered on ClinicalTrials.gov. The announcement traces to a single paid newswire release in January 2026, syndicated into around twenty local newspaper press-release sections, which reads like broad coverage but is one purchased placement. |
Frequently Asked Questions: Semaglutide Oral vs NA-931
What is the difference between Semaglutide Oral and NA-931?
Semaglutide Oral is a weight loss peptide that oral semaglutide is the pill version of the same glp-1 peptide found in ozempic and wegovy, sold for type 2 diabetes as rybelsus. the trick that makes it work is an absorption enhancer called snac, which shields the peptide from stomach acid and helps it cross the gut lining. lower doses are approved for diabetes, and higher 25 mg doses have now been approved as the first glp-1 pill for weight loss. NA-931 is a weight loss peptide that na-931 (bioglutide) is cyclic glycine-proline, a two-amino-acid ring that occurs naturally as a breakdown product of igf-1. its developer, biomed industries, describes it as an oral once-daily agonist at four receptors at once - igf-1, glp-1, gip and glucagon - and has reported 13 to 15 percent weight loss in a 126-person phase 2 trial. those numbers have only ever appeared in conference abstracts, never in a peer-reviewed paper, and no trial results have been filed to clinicaltrials.gov. the same molecule is already sold as a consumer brain-health supplement and as a sigma-aldrich catalogue chemical, which makes it unusually cheap to source and unusually hard to verify. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semaglutide Oral or NA-931?
Neither is universally "better" - the choice depends on your specific goals. Semaglutide Oral is typically used for weight loss purposes, while NA-931 is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semaglutide Oral and NA-931 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semaglutide Oral and NA-931 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.